2023 Fall Clinical Virtual Grand Rounds
2023 Virtual Grand Rounds Session 5: March 29, 2023 - Highlights from the AAD
About
Fall Clinical Virtual Grand Rounds consists of regularly scheduled CME sessions on a variety of dermatological diseases and tools, delivered by the top experts in dermatology.
Please join us for this week's session:
Wednesday, March 29, 2023
8 PM ET/ 5 PM PT
Highlights from the AAD
Part I: Highlights from the AAD 2023 on Inflammatory Skin Diseases: Atopic dermatitis, Alopecia, Acne and Rosacea, Psoriasis and More
Part II: Highlights from the AAD 2023 on Pediatric dermatology, Skin Cancers, and Aesthetic Dermatology
Availability
In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:
March 29, 2023
March 29, 2024
Learning Objectives
At the completion of this activity, participants should be better able to:
Apply the latest evidence-based guidelines and data to management of patients with a range of dermatologic conditions
Evaluate findings from recent clinical trials to identify appropriate adjustments to current treatment and management strategies
Recognize the benefits of newly studied treatments
Intended Audience
Faculty
April Armstrong, MD, MPH
Chief, Division of Dermatology
David Geffen School of Medicine at UCLA
Los Angeles, CA
Brett King, MD, PhD
Associate Professor of Dermatology
Yale School of Medicine
New Haven, CT
Peter Lio, MD
Clinical Assistant Professor of Dermatology Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL
Minnelly Luu, MD
Chief, Pediatric Dermatology
Children's Hospital Los Angeles
Associate Professor of Dermatology
USC Keck School of Medicine
Los Angeles, CA
Mark Nestor, MD, PhD
Director of Center for Clinical and Cosmetic Research
Voluntary Professor, Dermatology
University of Miami, Miller School of Medicine
Miami, FL
Linda Stein Gold, MD
Director Clinical Research
Henry Ford Health System
Detroit, MI
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Institute for Continuing Healthcare Education and CMEsquared. The Institute is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The Institute for Continuing Healthcare Education designates this live and enduring activity for a maximum of 1 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures & Disclaimers
CONFLICTS OF INTEREST/DISCLOSURES
In accordance with the ACCME Standards for Commercial Support, balance, independence, objectivity, and scientific rigor are ensured in all CME activities. This requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with any ineligible companies. In addition, the content of this material has been approved by an independent peer reviewer.
Disclosures are as follows:
Grant/Research Support: BMS, Leo, UCB, Lilly, Dermavant, Dermira, Pfizer, AbbVie, ASLAN, BI, EPI, Incyte, Janssen
Consultant: Lilly, Novartis, Ortho, SUN, Dermavant, Dermira, Sanofi Regeneron, Pfizer, Parexel
Consultant: Abbvie, AltruBio Inc, Almirall, AnaptysBio, Arena Pharmaceuticals, Bioniz Therapeutics, Bristol-Meyers Squibb, Concert Pharmaceuticals Inc, Equillium, Horizon Therapeutics, Eli Lilly and Company, Incyte Corp, Janssen Pharmaceuticals, LEO Pharma, Otsuka/Visterra Inc, Pfizer Inc, Regeneron, Sanofi Genzyme, TWi Biotechnology Inc, and Viela Bio
Speakers’ Bureau or Honoraria: Abbvie, Eli Lilly and Company, Incyte, Pfizer Inc, Regeneron and Sanofi Genzyme
Other Financial Benefit: Clinical trial investigator for AnaptysBio, Arena Pharmaceuticals, Concert Pharmaceuticals Inc, Eli Lilly and Company, NIH, Pfizer Inc.
has disclosed that they have no relevant financial relationships with any Ineligible Company in the past 24 months.
has disclosed that they have no relevant financial relationships with any Ineligible Company in the past 24 months.
Grant/Research Support: CROMA Pharma, Galderma, Merz
Consultant: CROMA Pharma, Revian, Sensus
Speakers’ Bureau or Honoraria: Allergan, AMP, Galderma, Hugel, Sensus
Grant/Research Support: Arcutis, BMS, Incyte, Dermavant, Galderma, Lilly, AbbVie
Consultant: Arcutis, BMS, Incyte, Dermavant, Galderma, Lilly, AbbVie
Speakers’ Bureau or Honoraria: Leo, AbbVie, Almirall, Galderma, Pfizer, Sanofi, Regeneron
The planners have disclosed that they have no relevant financial relationships with any Ineligible Company in the past 24 months.
The Institute discloses that all relevant conflicts have been satisfactorily mitigated.